|  | Study Entry | Scheduled Assessments (± 3 days as inpatient; ± 5 days as outpatient) | |||||
---|---|---|---|---|---|---|---|---|
 |  |  | Day 0 | Day 7 | Day 14 | Day 28 | Day 60 | Day 100 |
Demographics/Baseline characteristics | Trial Case Number | x | Â | Â | Â | Â | Â | Â |
 | Date of Birth | x |  |  |  |  |  |  |
 | Gender | x |  |  |  |  |  |  |
 | Indication for HSCT | x |  |  |  |  |  |  |
 | Stem cell Source | x |  |  |  |  |  |  |
 | CD34 cell count | x |  |  |  |  |  |  |
 | Donor Type (allos only) | x |  |  |  |  |  |  |
 | HLA compatibility (allos only) | x |  |  |  |  |  |  |
 | ABO blood type | x |  |  |  |  |  |  |
 | ABO compatibility (allos only) | x |  |  |  |  |  |  |
 | CMV compatibility (allos only) | x |  |  |  |  |  |  |
 | Karnofsky Functional Scale | x |  |  |  |  |  |  |
 | Conditioning regimen | x |  |  |  |  |  |  |
 | HCT-CI | x |  |  |  |  |  |  |
 | CBC | x | all available values | |||||
Quality of Life Scales | EQ-5D and FACT-BMT†| x |  | x | x | x | x | x |
Transfusion Assessments | Red Cells Transfusion Assessment | As needed | ||||||
 | Platelets Transfusion Assessment | As needed | ||||||
 | Plasma and Cryoprecipitate Transfusion Assessment | As needed | ||||||
Transplant Assessments | Bleeding Assessment | Â | Â | x | x | Â | x | |
 | Infection Assessment |  |  | x | x |  | x | |
 | VOD Assessment# |  |  |  | x |  |  | |
 | Bearman Toxicity Assessment^ |  |  |  | x |  |  | |
 | aGVHD* |  |  |  |  |  | x | |
 | Admission to ICU | As needed | ||||||
 | Hospital Admission | As needed | ||||||
 | Mortality Assessment |  |  |  |  |  | x |